ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Calithera, a spin-off from the University of California, San Francisco, has raised $40 million in its first round of financing. The biotech firm was formed to commercialize caspase activation technology developed in the lab of Jim Wells, chair of the pharmaceutical chemistry department in UCSF’s School of Pharmacy. Wells has found several small molecules that convert caspases from an inactive form into enzymes that destroy cancer cells. Morgenthaler Ventures led the financing round. Mission Bay Capital, U.S. Venture Partners, Advanced Technology Ventures, and Delphi Ventures all participated.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X